1. Home
  2. EBC vs CRSP Comparison

EBC vs CRSP Comparison

Compare EBC & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eastern Bankshares Inc.

EBC

Eastern Bankshares Inc.

HOLD

Current Price

$19.05

Market Cap

4.6B

Sector

Finance

ML Signal

HOLD

Logo CRISPR Therapeutics AG

CRSP

CRISPR Therapeutics AG

HOLD

Current Price

$56.10

Market Cap

4.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EBC
CRSP
Founded
1818
2013
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Accident &Health Insurance
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.6B
4.7B
IPO Year
2020
2016

Fundamental Metrics

Financial Performance
Metric
EBC
CRSP
Price
$19.05
$56.10
Analyst Decision
Buy
Buy
Analyst Count
4
17
Target Price
$22.13
$70.00
AVG Volume (30 Days)
1.9M
1.4M
Earning Date
04-23-2026
05-15-2026
Dividend Yield
2.68%
N/A
EPS Growth
N/A
N/A
EPS
0.43
N/A
Revenue
$134,091,000.00
$289,590,000.00
Revenue This Year
$73.53
$1,070.60
Revenue Next Year
$4.63
$100.28
P/E Ratio
$45.05
N/A
Revenue Growth
19.07
9169.85
52 Week Low
$13.51
$30.06
52 Week High
$22.58
$78.48

Technical Indicators

Market Signals
Indicator
EBC
CRSP
Relative Strength Index (RSI) 33.66 51.07
Support Level $18.33 $51.64
Resistance Level $20.07 $60.63
Average True Range (ATR) 0.65 3.15
MACD -0.28 0.33
Stochastic Oscillator 14.96 41.16

Price Performance

Historical Comparison
EBC
CRSP

About EBC Eastern Bankshares Inc.

Eastern Bankshares Inc is a commercial bank that caters its products and services to retail, commercial, and small business customers. Its diversified products and services include lending, deposit, wealth management, and insurance products. The company has one operating segment; Banking business which offers a range of banking lending, savings, and small business offerings, and its wealth management and trust operations.

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Share on Social Networks: